Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3′,5′-Cyclic Monophosphate–Dependent Protein Kinase
- 4 November 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 108 (18), 2172-2183
- https://doi.org/10.1161/01.cir.0000094403.78467.c3
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human PlateletsStroke, 2003
- Direct activation of PDE5 by cGMPThe Journal of cell biology, 2003
- Upregulation of Vascular NAD(P)H Oxidase Subunit gp91phox and Impairment of the Nitric Oxide Signal Transduction Pathway in HypertensionBiochemical and Biophysical Research Communications, 2001
- Sildenafil citrate: A therapeutic updateClinical Therapeutics, 2001
- Phosphorylation of the Vasodilator-stimulated Phosphoprotein Regulates Its Interaction with ActinJournal of Biological Chemistry, 2000
- Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth MuscleJournal of Biological Chemistry, 2000
- Increased Adhesion and Aggregation of Platelets Lacking Cyclic Guanosine 3′,5′-Monophosphate Kinase IThe Journal of Experimental Medicine, 1999
- Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase IIScience, 1996
- Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.JCI Insight, 1996
- Phosphorylation of smg p21B/rap1B p21 by cyclic GMP‐dependent protein kinaseFEBS Letters, 1992